These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 18775310)

  • 1. Chemical and biological approaches synergize to ameliorate protein-folding diseases.
    Mu TW; Ong DS; Wang YJ; Balch WE; Yates JR; Segatori L; Kelly JW
    Cell; 2008 Sep; 134(5):769-81. PubMed ID: 18775310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TFEB regulates lysosomal proteostasis.
    Song W; Wang F; Savini M; Ake A; di Ronza A; Sardiello M; Segatori L
    Hum Mol Genet; 2013 May; 22(10):1994-2009. PubMed ID: 23393155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases.
    Wang F; Song W; Brancati G; Segatori L
    J Biol Chem; 2011 Dec; 286(50):43454-64. PubMed ID: 22006919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of the proteostasis network of plant cells promotes the post-endoplasmic reticulum trafficking of recombinant mutant (L444P) human β-glucocerebrosidase.
    Babajani G; Kermode AR
    Plant Signal Behav; 2014; 9(3):e28714. PubMed ID: 24713615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lacidipine remodels protein folding and Ca 2+ homeostasis in Gaucher's disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase.
    Wang F; Chou A; Segatori L
    Chem Biol; 2011 Jun; 18(6):766-76. PubMed ID: 21700212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients.
    Tropak MB; Reid SP; Guiral M; Withers SG; Mahuran D
    J Biol Chem; 2004 Apr; 279(14):13478-87. PubMed ID: 14724290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic Approaches for Adapting Proteostasis in the Secretory Pathway to Ameliorate Protein Conformational Diseases.
    Kelly JW
    Cold Spring Harb Perspect Biol; 2020 May; 12(5):. PubMed ID: 31088828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FKBP10 depletion enhances glucocerebrosidase proteostasis in Gaucher disease fibroblasts.
    Ong DS; Wang YJ; Tan YL; Yates JR; Mu TW; Kelly JW
    Chem Biol; 2013 Mar; 20(3):403-15. PubMed ID: 23434032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and chemical approaches to diseases of proteostasis deficiency.
    Powers ET; Morimoto RI; Dillin A; Kelly JW; Balch WE
    Annu Rev Biochem; 2009; 78():959-91. PubMed ID: 19298183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteostasis regulators as potential rescuers of PMM2 activity.
    Vilas A; Yuste-Checa P; Gallego D; Desviat LR; Ugarte M; Pérez-Cerda C; Gámez A; Pérez B
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165777. PubMed ID: 32222543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis.
    Ong DS; Mu TW; Palmer AE; Kelly JW
    Nat Chem Biol; 2010 Jun; 6(6):424-32. PubMed ID: 20453863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ca2+ homeostasis modulation enhances the amenability of L444P glucosylcerebrosidase to proteostasis regulation in patient-derived fibroblasts.
    Wang F; Agnello G; Sotolongo N; Segatori L
    ACS Chem Biol; 2011 Feb; 6(2):158-68. PubMed ID: 21043486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using pharmacological chaperones to restore proteostasis.
    Wang YJ; Di XJ; Mu TW
    Pharmacol Res; 2014 May; 83():3-9. PubMed ID: 24747662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What can cell biology tell us about heterogeneity in lysosomal storage diseases?
    Gieselmann V
    Acta Paediatr Suppl; 2005 Mar; 94(447):80-6; discussion 79. PubMed ID: 15895717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
    Hou ZS; Ulloa-Aguirre A; Tao YX
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tay-Sachs disease mutations in HEXA target the α chain of hexosaminidase A to endoplasmic reticulum-associated degradation.
    Dersh D; Iwamoto Y; Argon Y
    Mol Biol Cell; 2016 Dec; 27(24):3813-3827. PubMed ID: 27682588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases.
    Jakóbkiewicz-Banecka J; Wegrzyn A; Wegrzyn G
    J Appl Genet; 2007; 48(4):383-8. PubMed ID: 17998597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.
    Mohamed FE; Al-Gazali L; Al-Jasmi F; Ali BR
    Front Pharmacol; 2017; 8():448. PubMed ID: 28736525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.